PL368816A1 - 3-substituted-4-pyrimidone derivatives - Google Patents

3-substituted-4-pyrimidone derivatives

Info

Publication number
PL368816A1
PL368816A1 PL02368816A PL36881602A PL368816A1 PL 368816 A1 PL368816 A1 PL 368816A1 PL 02368816 A PL02368816 A PL 02368816A PL 36881602 A PL36881602 A PL 36881602A PL 368816 A1 PL368816 A1 PL 368816A1
Authority
PL
Poland
Prior art keywords
substituted
pyrimidone derivatives
pyrimidone
derivatives
Prior art date
Application number
PL02368816A
Other languages
English (en)
Polish (pl)
Inventor
Fumiaki Uehara
Keiichi Aritomo
Aya Shoda
Shinsuke Hiki
Masahiro Okuyama
Yoshihiro Usui
Mitsuru Ooizumi
Kazutoshi Watanabe
Original Assignee
Mitsubishi Pharma Corporation
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corporation, Sanofi-Synthelabo filed Critical Mitsubishi Pharma Corporation
Publication of PL368816A1 publication Critical patent/PL368816A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL02368816A 2001-09-21 2002-09-20 3-substituted-4-pyrimidone derivatives PL368816A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001331675 2001-09-21
JP2001331678 2001-09-21
JP2001331676 2001-09-21
JP2001331674 2001-09-21

Publications (1)

Publication Number Publication Date
PL368816A1 true PL368816A1 (en) 2005-04-04

Family

ID=27482650

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02368816A PL368816A1 (en) 2001-09-21 2002-09-20 3-substituted-4-pyrimidone derivatives

Country Status (23)

Country Link
US (1) US7572793B2 (fr)
EP (1) EP1427709B1 (fr)
JP (1) JP4368682B2 (fr)
KR (1) KR100754596B1 (fr)
CN (1) CN1319950C (fr)
AR (2) AR043700A1 (fr)
AT (1) ATE312827T1 (fr)
AU (1) AU2002337498B2 (fr)
BR (1) BR0212893A (fr)
CA (1) CA2460177C (fr)
CY (1) CY1105554T1 (fr)
DE (1) DE60208051T2 (fr)
DK (1) DK1427709T3 (fr)
EA (1) EA007224B1 (fr)
ES (1) ES2256540T3 (fr)
HU (1) HUP0401898A3 (fr)
IL (2) IL160701A0 (fr)
MX (1) MXPA04002661A (fr)
NO (1) NO326694B1 (fr)
NZ (1) NZ531637A (fr)
PL (1) PL368816A1 (fr)
TW (1) TWI303171B (fr)
WO (1) WO2003027080A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR023052A1 (es) 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
EP1427720B1 (fr) 2001-09-21 2009-03-04 Mitsubishi Tanabe Pharma Corporation Derives de 3-substitue-4-pyrimidone
JP4616003B2 (ja) * 2002-12-16 2011-01-19 田辺三菱製薬株式会社 ３−置換−４−ピリミドン誘導体
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
MXPA06001601A (es) 2003-08-13 2006-08-25 Takeda Pharmaceutical Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
WO2005026148A1 (fr) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Inhibiteurs de la dipeptidylpeptidase
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
BRPI0515851A (pt) 2004-09-29 2008-08-12 Mitsubishi Pharma Corp composto de pirimidona
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
TW200740779A (en) * 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
NZ566799A (en) 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
WO2007035629A2 (fr) 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidylpeptidase
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
CA2661334C (fr) * 2006-08-23 2011-11-29 Pfizer Products Inc. Composes de pyrimidone en tant qu'inhibiteurs de gsk-3
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
MX2010002765A (es) 2007-09-14 2010-05-19 Mitsubishi Tanabe Pharma Corp Derivado de 6-pirimidinil-pirimid-4-ona.
CN101842371A (zh) * 2007-09-14 2010-09-22 赛诺菲-安万特公司 3-甲基-2-((2S)-2-(4-(3-甲基-1,2,4-噁二唑-5-基)苯基)吗啉基)-6-(嘧啶-4-基)嘧啶-4(3H)-酮作为tau蛋白激酶抑制剂
EP2078717A1 (fr) 2008-01-11 2009-07-15 sanofi-aventis Dérivé de la 6-pyrimidinyl-pyrimid-2-one
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
US9006232B2 (en) 2009-08-13 2015-04-14 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives
JP5442852B2 (ja) 2009-08-13 2014-03-12 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
EP2550361B1 (fr) 2010-03-25 2017-02-08 The J. David Gladstone Institutes Compositions et procédés pour traiter des troubles neurologiques
WO2012145169A2 (fr) 2011-04-21 2012-10-26 The Regents Of The University Of California Nanoparticules magnétiques fonctionnalisées et leur utilisation dans l'imagerie de dépôts amyloïdes et d'enchevêtrements neurofibrillaires
BR112014015832A8 (pt) * 2012-01-12 2017-07-04 Hoffmann La Roche derivados heterocíclicos como receptores associados com aminas vistigiais (taars)
EP2885010B1 (fr) 2012-08-16 2020-01-01 Ipierian, Inc. Méthodes de traitement d'une tauopathie
WO2014066744A2 (fr) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anticorps de la c1s anti-complément et leurs utilisations
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
SMT202000401T1 (it) 2013-06-10 2020-11-10 Ipierian Inc Metodi di trattamento di una taupatia

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US187004A (en) * 1877-02-06 Improvement in water-wheels
JPS559099B2 (fr) 1972-08-07 1980-03-07
JPS4935633A (fr) 1972-08-09 1974-04-02
JPS5124008B2 (fr) 1972-08-10 1976-07-21
JPS4935632A (fr) 1972-08-10 1974-04-02
JPS5271481A (en) 1975-12-10 1977-06-14 Yoshitomi Pharmaceut Ind Ltd Synthesis of pyridylpyrimidines
JPS52139085A (en) 1976-05-13 1977-11-19 Hokuriku Pharmaceutical 22allylpiperazine derivative and method for its preparation
US4507302A (en) * 1979-03-19 1985-03-26 The Upjohn Company Method for treating arthritis with 6-aryl pyrimidine compounds
US4619933A (en) * 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
US4725600A (en) 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
EP0338686B1 (fr) * 1988-04-22 1994-06-22 Zeneca Limited Dérivés de pyrimidinone
EP0354179B1 (fr) 1988-07-29 1994-08-17 Ciba-Geigy Ag Thiouracils comme stabilisants pour des polymères contenant du chlore
WO1993011231A1 (fr) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Outils de diagnostic et de traitement de la maladie d'alzheimer
DE4206145A1 (de) 1992-02-28 1993-09-02 Basf Ag Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide
JP3324611B2 (ja) 1992-07-03 2002-09-17 三菱化学株式会社 タウ蛋白質のリン酸化方法
JPH06329551A (ja) 1993-03-22 1994-11-29 Mitsubishi Kasei Corp アルツハイマー病の予防または治療薬およびそのスクリーニング方法
NZ274978A (en) * 1993-10-12 1998-04-27 Du Pont Merck Pharma 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
AR048564A1 (es) 1996-12-05 2006-05-10 Amgen Inc Compuestos de pirimidina sustituidos,composicion farmaceutica y usos para la fabricacion de medicamentos particularmente para el tratamiento de enfermedades mediadas por tnf-alfa, il-1 beta, il-6 y/o il-8
CA2274093C (fr) 1996-12-05 2006-11-07 Amgen Inc. Composes substitues a base de pyrimidone et de pyridone et procedes d'utilisation
ES2203937T3 (es) * 1997-03-26 2004-04-16 Taisho Pharmaceutical Co., Ltd Derivados de 4-tetrahidropiridilpirimidina.
AR023052A1 (es) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
YU63802A (sh) * 2000-02-25 2005-06-10 F. Hoffmann-La Roche Ag. Modulatori adenozinskih receptora
AU2001262150A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(nitrogen-heterocyclic)pyrimidone derivatives
EP1136482A1 (fr) 2000-03-23 2001-09-26 Sanofi-Synthelabo Dérivés de 2-amino-3-(alkyl)-pyrimidone comme inhibiteurs de GSK3bêta
EP1427720B1 (fr) 2001-09-21 2009-03-04 Mitsubishi Tanabe Pharma Corporation Derives de 3-substitue-4-pyrimidone
JP4616003B2 (ja) 2002-12-16 2011-01-19 田辺三菱製薬株式会社 ３−置換−４−ピリミドン誘導体
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
JP4368682B2 (ja) 2009-11-18
HUP0401898A2 (hu) 2004-12-28
WO2003027080A1 (fr) 2003-04-03
US20050130967A1 (en) 2005-06-16
KR20040054690A (ko) 2004-06-25
NZ531637A (en) 2005-12-23
CN1555367A (zh) 2004-12-15
HK1068608A1 (en) 2005-04-29
CY1105554T1 (el) 2010-07-28
EA200400452A1 (ru) 2004-08-26
EP1427709A1 (fr) 2004-06-16
DE60208051D1 (de) 2006-01-19
EA007224B1 (ru) 2006-08-25
CA2460177A1 (fr) 2003-04-03
BR0212893A (pt) 2004-08-03
AR036604A1 (es) 2004-09-22
DK1427709T3 (da) 2006-04-03
AU2002337498B2 (en) 2006-08-10
NO326694B1 (no) 2009-02-02
ATE312827T1 (de) 2005-12-15
NO20041604L (no) 2004-06-17
US7572793B2 (en) 2009-08-11
IL160701A (en) 2009-06-15
IL160701A0 (en) 2004-08-31
CA2460177C (fr) 2010-03-23
CN1319950C (zh) 2007-06-06
AR043700A1 (es) 2005-08-10
TWI303171B (en) 2008-11-21
JP2005510472A (ja) 2005-04-21
HUP0401898A3 (en) 2005-08-29
MXPA04002661A (es) 2004-11-22
ES2256540T3 (es) 2006-07-16
DE60208051T2 (de) 2006-06-22
EP1427709B1 (fr) 2005-12-14
KR100754596B1 (ko) 2007-09-05

Similar Documents

Publication Publication Date Title
ZA200309522B (en) Substituted cyclohexane-1-4diamine derivatives
IL160701A0 (en) 3-substituted-4-pyrimidone derivatives
DE60217162D1 (en) Tetrafluorethen-perfluorbutylethen-copolymer
DE50202400D1 (en) Baw-resonator
DE60217478D1 (en) Sychrongleichrichter
DE60231477D1 (en) Imidazolderivate
IL158388A0 (en) Novel arylheteroalkylamine derivatives
DE60141362D1 (en) Ösophagus-stoma-knopf
DE50202633D1 (en) Ophthalmoskop
DE60218514D1 (en) Polyolefin-kunststoffrohre
HUP0303449A3 (en) Substituted benzofuran-2-carboxamides derivatives
EP1353546A4 (fr) Procede et dispositif de surveillance de pulsation pour dispositif de traite
EP1417203A4 (fr) S-6-hydroxy-buspirone
HUP0303186A3 (en) 4-aminobenzopyran derivatives
HUP0401949A3 (en) 4-imidazolin-2-one derivatives
HUP0500026A3 (en) N-heteroarylnicotinamide derivatives
DE60226167D1 (en) Computersystem-e/a-knoten
IL159064A0 (en) New phenylalkyloxy- phenyl derivatives
EP1364954A4 (fr) Derives de dicarba-(closo)-dodecarborane
DE50214962D1 (en) Heterocyclylarylsulfonamide
DE50201028D1 (en) Diarylgelbpigmentpraeparationen
AU2001100134A4 (en) Enviro-trap
SI1427709T1 (sl) 3-substituirani-4-pirimidonski derivati
GB0117479D0 (en) Jetters
CA93646S (en) Fauteuil

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)